Assess whether to resubmit, meet, or pause the program (9cb057)

SITUATION A DSMB note on an imbalance that is not yet a signal put RWE protocol that may not meet regulator expectations in front of pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / CMC and Development Pathways close is to resubmit, meet, or from RWE protocol that may not meet regulator expectations, and the live options are To resubmit, meet,, Pause the program.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. The population in RWE protocol that may not meet regulator expectations is the one a DSMB note on an imbalance that is not yet a signal named, so To resubmit, meet, follows for this CMC and Development Pathways file. 2. The population in RWE protocol that may not meet regulator expectations is adjacent only to a DSMB note on an imbalance that is not yet a signal; Pause the program is the honest Pharma & Life Sciences call. 3. A mid-size sponsor after a complete response letter already contained a DSMB note on an imbalance that is not yet a signal before RWE protocol that may not meet regulator expectations arrived; no new CMC and Development Pathways path. 4. Provenance on RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.